<DOC>
	<DOCNO>NCT02176382</DOCNO>
	<brief_summary>The aim study assess effect antiresorptive medication combination standard dose alternate dose teriparatide .</brief_summary>
	<brief_title>Denosumab Teriparatide Study ( DATA-2 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>woman age 45+ postmenopausal osteoporotic high risk fracture significant previous use bone health modifying treatment</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>